* Newstin.com is for sale! * After achieving our strategic milestone, we are offering for sale: Newstin.com and all 14 related domains featuring 1 million unique visitors per month + continuously updated news database of 37 million articles in 12 world languages from 166,000 global and weighted sources + 2.1 billion metadata * To seize this unique chance, contact invest@newstin.com. * Newstin.com is for sale! *

ASCO

                   
genengnews.com: Genetic Engineering genengnews.com

Enzon Reports Solid Second Quarter 2008 Results

genengnews.com
Aug 6, 2008
        

News source: Business Wire Enzon Pharmaceuticals, Inc. today announced solid second quarter 2008 financial results. For the three months ended June 30, 2008, Enzon reported a net loss of $1.7 million or $0.04 on a diluted...

add comment
                   

CORRECTING and REPLACING AVANT Reports Second Quarter and Six Month Financial Results (Business...

yahoo.com
Aug 6, 2008
        

Wednesday August 6, 8:46 am ET Conference Call Wednesday, August 6 at 9:00 a.m. Eastern Time NEEDHAM, Mass.--(BUSINESS WIRE)--Please replace the release with the following corrected version due to multiple revisions. Important...

add comment

Exelixis Announces Second Quarter 2008 Financial Results (Business Wire)

yahoo.com
Aug 5, 2008
        

Tuesday August 5, 4:08 pm ET SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq:EXEL - News ) today reported financial results for the second quarter ended June 30, 2008. Revenues for the quarter ended June...

add comment
                   

U.S. Preventive Services Task Force Does Not Recommend PSA Screening in Elderly Men

cancerconsultants.com
Aug 5, 2008 3 related
        

Members of the U.S. Preventive Services Task Force have concluded that there is still insufficient evidence to recommend PSA screening in men 75 years of age or younger. The details of these recommendations were published in...

add comment

Seattle Genetics Reports Second Quarter 2008 Financial Results (Business Wire)

yahoo.com
Jul 22, 2008 4 related
        

Tuesday July 22, 4:15 pm ET -- Conference call today at 5:00 p.m. ET -- BOTHELL, Wash.--(BUSINESS WIRE)--Seattle Genetics, Inc. (Nasdaq:SGEN - News ) today reported financial results for the second quarter and six months ended...

add comment
                   

Protherics Plc Interim Management Statement

redorbit.com
Jul 22, 2008 6 related
        

Protherics PLC AGM and Interim Management Statement London, UK; Brentwood, TN, US; 22 July 2008 - Protherics PLC ("Protherics" or the "Company"), the international biopharmaceutical company focused on critical care and cancer,...

add comment
                   
genengnews.com: Genetic Engineering genengnews.com

Exelixis Initiates Phase 3 Trial of XL184 in Medullary Thyroid Cancer

genengnews.com
Jul 21, 2008 9 related
        

News source: Business Wire Exelixis, Inc. announced today that the phase 3 registration trial of XL184 as a potential treatment for medullary thyroid cancer (MTC) has been initiated. "We are thrilled that the pivotal trial for...

add comment
                   

Genentech Q2 2008 Earnings Call Transcript

pharmiweb.co.uk
Jul 18, 2008
        

posted on: July 14, 2008 | about stocks: DNA Executives Kathee Littrell - During the first half of 2008, we also successfully achieved many of our key business goals by obtaining accelerated approval of Avastin for metastatic...

add comment

LAB21 Limited Expands Companion Diagnostic Cancer Testing Service Internationally

biospace.com
Jul 17, 2008 1 related
        

Cambridge, 17th July 2008 ... Lab21, a quality provider of healthcare diagnostic products and state of the art diagnostic services, is pleased to offer its newly launched K-RAS gene mutation and its epidermal growth factor...

add comment
                   
istockanalyst.com: t-dm1-weekly-graph.PNG istockanalyst.com

Immunogen at ASCO Annual Meeting 2008

istockanalyst.com
Jul 15, 2008 1 related
        

Many terms can be used to describe Immunogen’s recent stock behavior, but it seems the word “schizophrenic” is the most suitable one. T-DM1’s Clinical Data Genentech presented data from two phase I clinical trials with T-DM1,...

add comment
1 2 3 4 5 next »